How effective is Ocriplasmin in the treatment of maculopathy?

Ocriplasmin (Ocriplasmin) is an enzyme preparation used to treat vitreo-macular traction syndrome (VMT) and related diseases associated with epiretinal membrane (ERM). Its mechanism of action is mainly to specifically cleave the protein structures at the interface between the vitreous body and the macula, such as fibronectin and laminin, thereby promoting the natural peeling of the vitreous body and reducing the traction pressure on the macula. As a key area of u200bu200bthe retina responsible for central vision, the structural integrity of the macula directly affects visual clarity and visual function. VMT often causes macular deformation, visual distortion, or vision loss due to abnormal vitreous attachment, and Oakplasmin provides the possibility of non-surgical intervention through chemical vitreous peeling.

Clinical data show that Oakplasmin has certain advantages in improving the visual function of patients with mild to moderateVMT. Some patients can experience reduced macular traction, restoration of foveal shape, and significant improvement in vision and visual distortion symptoms after a single intravitreal injection. The advantage of using this enzyme preparation is that it avoids the surgical trauma, long postoperative recovery period and potential risks of complications caused by traditional vitrectomy (PPV), benefiting patients in terms of safety and comfort.

It is worth noting that the efficacy of Oak plasmin is greatly affected by the patient's epiretinal membrane thickness, vitreous attachment area andVMT severity. Patients with mild to moderate VMT respond better to enzymatic peeling, while for patients with thick epiretinal membrane or high traction, a single injection may not be enough to completely resolve the traction problem, and surgery or other treatments are required. In summary, Oakplasmin provides an innovative non-surgical treatment option, especially suitable for patients with early-stage or mild macular disease, that can improve visual function while reducing the risks of invasive treatments.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html